17Sep/20
Big Deal: Gilead Acquired Immunomedics for Nearly $20 Billion to Get Hot ADC Drugs
On Sept. 12, the Wall Street Journal reported that Gilead was reaching an acquisition agreement of more than $20 billion with Immunomedics to expand its oncology product pipeline, including trodelvy (sacituzumab govitecan),Read More…